132 related articles for article (PubMed ID: 11366583)
1. Biological treatment approaches, including Tat toxoid vaccine: interview with Robert Gallo, M.D. Interview by John S. James.
Gallo R
AIDS Treat News; 1999 Sep; (No 327):1-5. PubMed ID: 11366583
[TBL] [Abstract][Full Text] [Related]
2. New approaches to HIV treatment: interview with Robert Gallo. M.D. Interview by John S. James.
Gallo RC
AIDS Treat News; 1997 Dec; (No 285):1-5. PubMed ID: 11364917
[TBL] [Abstract][Full Text] [Related]
3. New finding on immune response to HIV Tat may contribute to vaccine, treatment.
James JS
AIDS Treat News; 2000 Sep; (351):4. PubMed ID: 12173551
[TBL] [Abstract][Full Text] [Related]
4. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.
Gallo RC
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8324-6. PubMed ID: 10411869
[No Abstract] [Full Text] [Related]
5. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
[TBL] [Abstract][Full Text] [Related]
6. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
7. Tat toxoid: its potential role as an HIV vaccine.
Lambert J
J Hum Virol; 1998; 1(4):249-50. PubMed ID: 10195248
[No Abstract] [Full Text] [Related]
8. Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine.
Gallo RC; Burny A; Zagury D
DNA Cell Biol; 2002 Sep; 21(9):611-8. PubMed ID: 12396603
[TBL] [Abstract][Full Text] [Related]
9. Fusion inhibitors, T-20; chemokine variants; tat and interferon antibodies: Gallo describes three new treatment approaches.
James JS
AIDS Treat News; 1998 Jul; (No 299):4-5. PubMed ID: 11365600
[TBL] [Abstract][Full Text] [Related]
10. HIV vaccines need to be developed: interview with Sam Avrett, International AIDS Vaccine Initiative. Interview by John S. James.
Avrett S
AIDS Treat News; 1997 May; (No 270):4-6. PubMed ID: 11364325
[TBL] [Abstract][Full Text] [Related]
11. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
12. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.
Ensoli B; Fiorelli V; Ensoli F; Cafaro A; Titti F; Buttò S; Monini P; Magnani M; Caputo A; Garaci E
AIDS; 2006 Nov; 20(18):2245-61. PubMed ID: 17117011
[No Abstract] [Full Text] [Related]
13. Avoiding deceptive imprinting of the immune response to HIV-1 infection in vaccine development.
Muller S
Int Rev Immunol; 2004; 23(5-6):423-36. PubMed ID: 15370274
[TBL] [Abstract][Full Text] [Related]
14. Some recent results on HIV pathogenesis with implications for therapy and vaccines.
Gallo RC; Garzino-Demo A
Cell Mol Biol (Noisy-le-grand); 2001 Nov; 47(7):1101-4. PubMed ID: 11838957
[TBL] [Abstract][Full Text] [Related]
15. Post-HAART therapy research.
Gallo RC
J Hum Virol; 1998; 1(2):67-8. PubMed ID: 10195233
[No Abstract] [Full Text] [Related]
16. HIV-1 Tat protein as a potential AIDS vaccine.
Goldstein G
Nat Med; 1996 Sep; 2(9):960-4. PubMed ID: 8782444
[No Abstract] [Full Text] [Related]
17. Full-length HIV-1 Tat protein necessary for a vaccine.
Opi S; Péloponèse JM; Esquieu D; Watkins J; Campbell G; De Mareuil J; Jeang KT; Yirrell DL; Kaleebu P; Loret EP
Vaccine; 2004 Aug; 22(23-24):3105-11. PubMed ID: 15297062
[TBL] [Abstract][Full Text] [Related]
18. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.
Mascarell L; Bauche C; Fayolle C; Diop OM; Dupuy M; Nougarede N; Perraut R; Ladant D; Leclerc C
Vaccine; 2006 Apr; 24(17):3490-9. PubMed ID: 16524647
[TBL] [Abstract][Full Text] [Related]
19. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application.
Caputo A; Brocca-Cofano E; Castaldello A; De Michele R; Altavilla G; Marchisio M; Gavioli R; Rolen U; Chiarantini L; Cerasi A; Dominici S; Magnani M; Cafaro A; Sparnacci K; Laus M; Tondelli L; Ensoli B
Vaccine; 2004 Jul; 22(21-22):2910-24. PubMed ID: 15246628
[TBL] [Abstract][Full Text] [Related]
20. Plant based HIV-1 vaccine candidate: Tat protein produced in spinach.
Karasev AV; Foulke S; Wellens C; Rich A; Shon KJ; Zwierzynski I; Hone D; Koprowski H; Reitz M
Vaccine; 2005 Mar; 23(15):1875-80. PubMed ID: 15734059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]